Published in final edited form as:

Bioorg Med Chem Lett. 2018 September 15; 28(17): 3014. doi:10.1016/j.bmcl.2018.07.022.

Corrigendum to “Challenges in the development of an M₄ PAM preclinical candidate: The discovery, SAR, and biological characterization of a series of azetidine-derived tertiary amides” [Bioorg. Med. Chem. Lett. 27(23) (2017) 5179-5184]

James C. Tarr^a, Michael R. Wood^{a,c}, Meredith J. Noetzel^{a,b}, Bruce J. Melancon^a, Atin Lamsal^{a,b}, Vincent B. Luscombe^a, Alice L. Rodriguez^a, Frank W. Byers^a, Sichen Chang^a, Hyekyung P. Cho^a, Darren W. Engers^a, Carrie K. Jones^{a,b}, Colleen M. Niswender^{a,b,e}, Michael W. Wood^d, Nicholas J. Brandon^d, Mark E. Duggan^d, P. Jeffrey Conn^{a,b,e}, Thomas M. Bridges^{a,b,*}, Craig W. Lindsley^{a,b,c,*}

^a Vanderbilt Center for Neuroscience Drug Discovery, Vanderbilt University School of Medicine, Nashville, TN 37232, USA

^b Department of Pharmacology, Vanderbilt University School of Medicine, Nashville, TN 37232, USA

^c Department of Chemistry, Vanderbilt University, Nashville, TN 37232, USA

^d Neuroscience Innovative Medicines, Astra Zeneca, 141 Portland Street, Cambridge, MA 02139, USA

^e Vanderbilt Kennedy Center, Vanderbilt University School of Medicine, Nashville, TN 37232, USA

The authors regret the incorrect format of the name of one of the authors on the original version of the manuscript. The authors would like to apologise for any inconvenience caused.

* Corresponding authors at: Vanderbilt Center for Neuroscience Drug Discovery, Vanderbilt University School of Medicine, Nashville, TN 37232, USA. address: craig.lindsley@vanderbilt.edu (C.W. Lindsley).